Drug therapy of attention deficit hyperactivity disorder: current trends

Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the m...

Full description

Saved in:
Bibliographic Details
Published in:Mens sana monographs 2012-01, Vol.10 (1), p.45-69
Main Authors: De Sousa, Avinash, Kalra, Gurvinder
Format: Article
Language:English
Subjects:
Attention deficit disorder
Attention-deficit hyperactivity disorder
Children & youth
Drug delivery systems
Drug therapy
Drug wholesalers
Drugs
Hyperactivity
Medical treatment
Review
Transdermal medication
Vehicles
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Attention deficit hyperactivity disorder is a developmental disorder with an age onset prior to 7 years. Children with ADHD have significantly lower ability to focus and sustain attention and also score higher on impulsivity and hyperactivity. Stimulants, such as methylphenidate, have remained the mainstay of ADHD treatment for decades with evidence supporting their use. However, recent years have seen emergence of newer drugs and drug delivery systems, like osmotic release oral systems and transdermal patches, to mention a few. The use of nonstimulant drugs like atomoxetine and various other drugs, such as α-agonists, and a few antidepressants, being used in an off-label manner, have added to the pharmacotherapy of ADHD. This review discusses current trends in drug therapy of ADHD and highlights the promise pharmacogenomics may hold in the future.
ISSN:0973-1229
1998-4014
DOI:10.4103/0973-1229.87261